Sign in
CompletedPhase 2

Valacyclovir for Mild Cognitive Impairment

Key facts

Who runs it
New York State Psychiatric Institute
Where
New York, United StatesSee the site
Trial code
Status
Completed
Phase
Phase 2
People taking part
50 people enrolled
Started
1 Feb 2021
Ended
23 Dec 2024
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Valacyclovir hydrochloride 500mg caplet
  • Placebo sugar pill caplet
Record updated
31 March 2026

Who can take part

Age
50 years to 95 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 21 criteriaShow less

Who can take part

  • Males and females ages 50-95. Females must be postmenopausal, defined as 12 consecutive months without menstruation. (Patient Report)
  • Diagnosis of MCI (includes eMCI and lMCI by ADNI criteria)(Neuropsychological Evaluation)
  • Folstein Mini Mental State (MMSE) greater than or equal to 23/30. (Neuropsychological Evaluation)
  • Patient retains capacity to consent for him/herself. (Physician Evaluation)
  • At screening, patients must test positive for serum antibodies to HSV1 or HSV2. (Laboratory Tests)
  • Use of cholinesterase inhibitors or memantine is not required but will be permitted. If already prescribed, doses of these medications must be stable for 1 month prior to study entry. Patients are permitted to receive cholinesterase inhibitors and/or memantine throughout the duration of the study. Any changes to the medication will be documented in the participant research chart. Medications given for other medical reasons, e.g., antidiabetic or anti-hypertensive medications, will not be altered for the purposes of this trial and the patient's primary physician may adjust such medications as medically indicated throughout the trial. Details of concomitant medication use will be documented at all visits and will be available for statistical analysis.(Patient Report)
  • Either PET amyloid scan positivity at screening, or prior CSF biomarker positive for AD. (Medical Records or through completing a PET scan as part of screening)

Who cannot take part

  • Current clinical diagnosis of schizophrenia, schizoaffective disorder, other psychosis, bipolar disorder or current major depression by DSM-5 criteria. Prior history of major depression will not be exclusionary. (Physician Evaluation)
  • For MRI, metal implants and pacemaker, and claustrophobia such that the patient refuses MRI. (Patient Report)
  • Radiation exposure in the prior 12 months that, together with 18F- Florbetapir will be above the FDA annual radiation exposure threshold. (Patient Report and Physician Evaluation)
  • Current or recent (past 6 months) alcohol or substance use disorder (DSM-5 criteria). (Physician Evaluation)
  • Current diagnosis of other major neurological disorders, including Parkinson's disease, multiple sclerosis,CNS infection, Huntington's disease, and amyotrophic lateral sclerosis. (Physician Evaluation)
  • Clinical stroke with residual clinical deficits. MRI findings of cerebrovascular disease (small infarcts, lacunes, periventricular disease) in the absence of clinical stroke with residual neurological deficits will not lead to exclusion. (Physician Evaluation)
  • Acute, severe, unstable medical illness. For cancer, patients with active illness or metastases in the last 12 months will be excluded, but past history of successfully treated cancer will not lead to exclusion. (Physician Evaluation)
  • Severe vision or hearing impairment that would prevent the participant from performing the psychometric tests accurately. This will be a clinical determination by the study physician without formal testing or audiometry.(Physician Evaluation)
  • Renal failure as determined by an estimated Glomerular Filtration Rate (GFR) < 44 ml/min/1.73m2. (Laboratory Report)
  • Serum vitamin B12 levels below the normal range. (Laboratory Report)
  • Patients with thyroid stimulating hormone (TSH) levels above 4.94 mlU/L. (Laboratory Report)
  • Active suicidal intent or plan based on clinical assessment. (SRMP Assessment by Study Physician)
  • Sitting blood pressure > 160/100 mm Hg. (Physician Evaluation)
  • Use of benzodiazepines in lorazepam equivalent doses equal to or greater than 2 mg daily. (Patient Report)

Where in United States

  • New York State Psychiatric InstituteNew York, United States

About the trial

What the trial wants to find out

Anti-viral treatment in Mild Cognitive Impairment (MCI) is a Phase II, placebo-controlled, 52-week trial using oral valacyclovir 4 g/day in 50 HSV seropositive, AD biomarker-positive, amnestic mild cognitive impairment (MCI) patients (eMCI and lMCI). The trial will directly address the long-standing viral etiology hypothesis of Alzheimer's disease (AD) which posits that viruses, particularly the very common herpes simplex virus-1 (HSV1) and herpes simplex virus-2 (HSV2), may be etiologic or contribute to the pathology of AD. This trial will intervene at an earlier stage (MCI). We will compare the repurposed drug valacyclovir to placebo in patients with amnestic MCI (eMCI and lMCI) in a randomized, double-blind, two-arm parallel group 52-week pilot trial. Our Phase II trial will be the first antiviral drug trial conducted in MCI.

The 2 groups in the trial

  • ValacyclovirExisting treatment, for comparison

    Oral valacyclovir will be distributed in 500mg caplets. Patients will take 8 caplets per day (total dose: 4 grams per day) for 52 weeks.

    Treatment: Valacyclovir hydrochloride 500mg caplet

  • PlaceboPlacebo, for comparison

    The oral placebo (sugar pill) will be distributed in 500mg caplets. Patients will take 8 caplets per day for 52 weeks.

    Treatment: Placebo sugar pill caplet

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Anti Viral Treatment in Mild Cognitive Impairment
Record updated
31 March 2026